Retinal Vein Occlusion and Diabetic Macular Oedema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with either Type 1 or Type 2 diabetes.
- People who have diabetic swelling in the central part of the retina (the area responsible for sharp vision), where the swelling measures more than 280 microns thick and fluid-filled pockets are visible within the retinal layers.
Who may not be able to join:
- People who have a history of any other disease affecting the central part of the retina.
- People in the anti-VEGF treatment group who have received a dexamethasone implant (a slow-release steroid placed in the eye) within the last six months.
- People in the dexamethasone implant group who have received anti-VEGF injections (a type of eye injection to reduce abnormal blood vessel growth) within the last two months.
- People who have previously had surgery on the inside of the eye involving the gel or retina.
- People who have previously had laser treatment applied to the central part of the retina.
- People who have previously had a full laser treatment of the retina, which is used for advanced diabetic eye disease.
- People who have had any eye surgery within the past three months.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Marita Grönlund, M.D. Prof, Göteborg University
Phone: +46738744867
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Serum levels of Vascular Endothelial Growth Factor (VEGF); Serum levels of interleukin 6 (IL-6); Serum levels of interleukin 8 (IL-8); Serum levels of monocyte chemoattractant protein 1 (MCP-1); Serum levels of angiopoietin 2 (Ang-2); Serum levels of placental growth factor (PlGF); Serum levels of tumor necrosis factor alpha (TNF-a); Serum levels of intercellular adhesion molecule 1 (ICAM-1)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.